Literature DB >> 24754714

Animal models of chronic obstructive pulmonary disease.

Michael Fricker1, Andrew Deane, Philip M Hansbro.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading global cause of mortality and chronic morbidity. Inhalation of cigarette smoke is the principal risk factor for development of this disease. COPD is a progressive disease that is typically characterised by chronic pulmonary inflammation, mucus hypersecretion, airway remodelling and emphysema that collectively reduce lung function. There are currently no therapies that effectively halt or reverse disease progression. It is hoped that the development of animal models that develop the hallmark features of COPD, in a short time frame, will aid in the identifying and testing of new therapeutic approaches. AREAS COVERED: The authors review the recent developments in mouse models of chronic cigarette smoke-induced COPD as well as the principal findings. Furthermore, the authors discuss the use of mouse models to understand the pathogenesis and the contribution of infectious exacerbations. They also discuss the investigations of the systemic co-morbidities of COPD (pulmonary hypertension, cachexia and osteoporosis). EXPERT OPINION: Recent advances in the field mark a point where animal models recapitulate the pathologies of COPD patients in a short time frame. They also reveal novel insights into the pathogenesis and potential treatment of this debilitating disease.

Entities:  

Keywords:  animal model; chemokine; chronic obstructive pulmonary disease; cigarette; cytokine; emphysema; guinea pig; immune system; inflammation; lung; lymphocyte; macrophage; mast cell; model; mouse; neutrophil; oxidative stress; protease; pulmonary; rat; reactive oxygen species; rodent; smoke; therapeutic; tobacco

Mesh:

Year:  2014        PMID: 24754714     DOI: 10.1517/17460441.2014.909805

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  42 in total

1.  Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases.

Authors:  Gang Liu; Marion A Cooley; Andrew G Jarnicki; Alan C-Y Hsu; Prema M Nair; Tatt Jhong Haw; Michael Fricker; Shaan L Gellatly; Richard Y Kim; Mark D Inman; Gavin Tjin; Peter A B Wark; Marjorie M Walker; Jay C Horvat; Brian G Oliver; W Scott Argraves; Darryl A Knight; Janette K Burgess; Philip M Hansbro
Journal:  JCI Insight       Date:  2016-06-16

2.  MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Authors:  Alan C-Y Hsu; Kamal Dua; Malcolm R Starkey; Tatt-Jhong Haw; Prema M Nair; Kristy Nichol; Nathan Zammit; Shane T Grey; Katherine J Baines; Paul S Foster; Philip M Hansbro; Peter A Wark
Journal:  JCI Insight       Date:  2017-04-06

3.  Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.

Authors:  Kent Miner; Katja Labitzke; Benxian Liu; Paul Wang; Kathryn Henckels; Kevin Gaida; Robin Elliott; Jian Jeffrey Chen; Longbin Liu; Anh Leith; Esther Trueblood; Kelly Hensley; Xing-Zhong Xia; Oliver Homann; Brian Bennett; Mike Fiorino; John Whoriskey; Gang Yu; Sabine Escobar; Min Wong; Teresa L Born; Alison Budelsky; Mike Comeau; Dirk Smith; Jonathan Phillips; James A Johnston; Joseph G McGivern; Kerstin Weikl; David Powers; Karl Kunzelmann; Deanna Mohn; Andreas Hochheimer; John K Sullivan
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

4.  The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model.

Authors:  A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro
Journal:  Br J Pharmacol       Date:  2016-10-12       Impact factor: 8.739

5.  IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.

Authors:  Malcolm R Starkey; Maximilian W Plank; Paolo Casolari; Alberto Papi; Stelios Pavlidis; Yike Guo; Guy J M Cameron; Tatt Jhong Haw; Anthony Tam; Ma'en Obiedat; Chantal Donovan; Nicole G Hansbro; Duc H Nguyen; Prema Mono Nair; Richard Y Kim; Jay C Horvat; Gerard E Kaiko; Scott K Durum; Peter A Wark; Don D Sin; Gaetano Caramori; Ian M Adcock; Paul S Foster; Philip M Hansbro
Journal:  Eur Respir J       Date:  2019-07-18       Impact factor: 16.671

6.  Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure.

Authors:  Zhongwei Sun; Feng Li; Xin Zhou; Wen Wang
Journal:  J Vis Exp       Date:  2017-08-25       Impact factor: 1.355

7.  Chronic exposure to electronic cigarettes results in impaired cardiovascular function in mice.

Authors:  I Mark Olfert; Evan DeVallance; Hannah Hoskinson; Kayla W Branyan; Stuart Clayton; Christopher R Pitzer; D Patrick Sullivan; Matthew J Breit; Zhongxin Wu; Powsiri Klinkhachorn; W Kyle Mandler; Brett H Erdreich; Barbara S Ducatman; Randall W Bryner; Piyali Dasgupta; Paul D Chantler
Journal:  J Appl Physiol (1985)       Date:  2017-11-02

Review 8.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

9.  Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis.

Authors:  Philip M Hansbro; Matthew J Hamilton; Michael Fricker; Shaan L Gellatly; Andrew G Jarnicki; Dominick Zheng; Sandra M Frei; G William Wong; Sahar Hamadi; Saijun Zhou; Paul S Foster; Steven A Krilis; Richard L Stevens
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

10.  Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction.

Authors:  Michael Fricker; Bridie J Goggins; Sean Mateer; Bernadette Jones; Richard Y Kim; Shaan L Gellatly; Andrew G Jarnicki; Nicholas Powell; Brian G Oliver; Graham Radford-Smith; Nicholas J Talley; Marjorie M Walker; Simon Keely; Philip M Hansbro
Journal:  JCI Insight       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.